Verastem Inc (VSTM)
NASDAQ:VSTM
Want to see VSTM full AI Analyst Report?
VSTM Stock Chart & Stats
$6.58
-$0.30(-4.59%)
At close: 4:00 PM EST
$6.58
-$0.30(-4.59%)
Day’s Range― - ―
52-Week Range$4.00 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.26M
Market Cap
$376.98M
Enterprise Value$220.05M
Total Cash (Recent Filing)$181.68M
Total Debt (Recent Filing)$85.47M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 06, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding87,873,640
10 Day Avg. Volume2,087,520
30 Day Avg. Volume2,258,108
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)9.35
Price to Sales (P/S)17.31
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue4.44
Enterprise Value/Gross Profit5.30
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$16.00Price Target Upside143.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$103.46M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In KRAS-mutant PatientsUpdated follow-up data indicate sustained efficacy and tolerability of the FAKZYNJA co-pack, with notably stronger benefit in KRAS‑mutant patients supporting targeted clinical use and uptake.
Commercial Launch PerformanceCommercial launch of avutometinib (FAKZYNJA) in low-grade serous ovarian cancer is outperforming expectations and provides a valuation floor that supports revenue visibility as adoption expands among academic and community physicians.
Regulatory Development PathwayStudy protocol amendments to pursue disease-specific registrational trials for the KRAS G12D inhibitor VS-7375 across multiple tumor types could streamline regulatory paths and increase the likelihood of accelerated approval opportunities.
Bears Say
Competitive LandscapeIntense competition in the KRAS inhibitor field and earlier safety concerns that required program adjustments could pressure market share and force additional changes to development plans.
Data Robustness And UncertaintySmall clinical and preclinical datasets limit confidence in the durability and generalizability of observed benefits, leaving positive signals dependent on confirmation in larger studies.
Market Adoption ConstraintsModest benefit in KRAS wild‑type patients and initial prescribing concentrated in later‑line recurrence may constrain near‑term utilization and delay broader movement of the therapy into earlier treatment lines.
Verastem News
VSTM FAQ
What was Verastem Inc’s price range in the past 12 months?
Verastem Inc lowest stock price was $4.00 and its highest was $11.24 in the past 12 months.
What is Verastem Inc’s market cap?
Verastem Inc’s market cap is $376.98M.
When is Verastem Inc’s upcoming earnings report date?
Verastem Inc’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were Verastem Inc’s earnings last quarter?
Verastem Inc released its earnings results on May 07, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.465 by $0.095.
Is Verastem Inc overvalued?
According to Wall Street analysts Verastem Inc’s price is currently Undervalued.
Does Verastem Inc pay dividends?
Verastem Inc does not currently pay dividends.
What is Verastem Inc’s EPS estimate?
Verastem Inc’s EPS estimate is -0.43.
How many shares outstanding does Verastem Inc have?
Verastem Inc has 87,873,640 shares outstanding.
What happened to Verastem Inc’s price movement after its last earnings report?
Verastem Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.465. Following the earnings report the stock price went down -13.604%.
Which hedge fund is a major shareholder of Verastem Inc?
Currently, no hedge funds are holding shares in VSTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (143.16% Upside)
$16.00 (143.16% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.27%
12-Months-Change
Fundamentals
Return on Equity
-486.41%
Trailing 12-Months
Asset Growth
72.98%
Trailing 12-Months
Company Description
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Company Deck
VSTM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging commercial and R&D progress with near-term operational and financial challenges. Highlights include steady product revenue growth ($18.7M in Q1; nearly $50M to date), expanding prescriber base (>400), improved PK/tolerability and progression of the 7375 Target-D program into Phase II registration-directed trials across PDAC, NSCLC and CRC (900 mg go-forward dose), and a cash position of $181.7M with runway into H1 2027. Lowlights include seasonal/access headwinds and early discontinuations reducing short-term refill volumes, high R&D and SG&A relative to current revenue leading to continued non-GAAP net losses (~$42.7M), immature duration/refill metrics, and practical dosing/formulation constraints at higher VS-7375 doses. Overall, positives (pipeline advancement, reimbursement and commercial actions, and encouraging VS-7375 data) are significant but offset by meaningful execution and funding risks in the near term.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$16.00
▲(143.16% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.52% Insiders
7.36% Mutual Funds
52.23% Other Institutional Investors
28.10% Public Companies and
Individual Investors